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Background: Previous studies have shown that preoperative anemia is correlated with the prognoses of various
solid tumors. This study was performed to determine the effect of preoperative anemia on relapse and survival in
patients with breast cancer.
Methods: A total of 2960 patients with breast cancer who underwent surgery between 2002 and 2008 at the
Sun Yat-sen University Cancer Center (Guangzhou, PR China) were evaluated in a retrospective analysis. A total of
2123 qualified patients were divided into an anemic group [hemoglobin (Hb) < 12.0 g/dL, N = 535)] and a nonanemic
group (Hb≥ 12.0 g/dL, N = 1588). The effects of anemia on local relapse-free survival (LRFS), lymph node metastasis-free
survival (LNMFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival (OS) were
assessed using Kaplan–Meier analysis. Independent prognostic factors were identified in the final multivariate Cox
proportional hazards regression model.
Results: Among the 2123 women who qualified for the analysis, 535 (25.2%) had a Hb level < 12.0 g/dL. The Kaplan–
Meier curves showed that anemic patients had worse LRFS, LNMFS, DMFS, RFS, and OS than nonanemic patients, even
in the same clinical stage of breast cancer. Cox proportional hazards regression model indicated that preoperative
anemia was an independent prognostic factor of LRFS, LNMFS, DMFS, RFS, and OS for patients with breast cancer.
Conclusions: Preoperative anemia was independently associated with poor prognosis of patients with breast cancer.
Keywords: Preoperative anemia, Breast cancer, Relapse, Survival, HypoxiaBackground
Anemia is a common complication in patients with can-
cer. It has been reported that between 30–90% of patients
with cancer have anemia [1]. Most studies have found that
pre-treatment anemia is associated with a worse prognosis
in cancer patients [2-5]. In a meta-analysis, anemic pa-
tients with lung cancer, cervicouterine carcinoma, head
and neck cancer, prostate cancer, lymphoma, and multiple
myeloma had shorter survival times than those without
anemia. The overall estimated increase in risk was 65%
(54–77%) [6]. Preoperative anemia, even mild anemia, was
independently associated with an increased risk of 30-day* Correspondence: zengwa@mail.sysu.edu.cn
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noncardiac surgery [7].
Breast cancer is one of the most common carcinomas
worldwide among women. Tumor size, nodal status,
histological grade, lymphovascular invasion (LVI), gene
profile and Human Epidermal Growth Factor Receptor-2
(HER-2)-positivity are strong prognostic factors of breast
cancer [8-10]. Although 41–82% of breast cancer patients
develop anemia before surgery, [1] few studies have ex-
plored the effects of preoperative anemia on the prognosis
of breast cancer. Whether preoperative anemia has a sig-
nificant adverse impact on relapse or survival in breast
cancer patients is still controversial [11,12].
In this study, we aimed to determine the effects of pre-
operative anemia on relapse (local relapse, lymph node me-
tastasis, distant metastasis, and overall relapse) and survival
(local relapse-free survival, lymph node metastasis-free sur-
vival, distant metastasis-free survival, relapse-free survival,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2407/14/844and overall survival) in patients undergoing breast cancer
surgery.
Methods
A total of 2960 patients with breast cancer who underwent
surgery between 2002 and 2008 at the Sun Yat-sen Univer-
sity Cancer Center (Guangzhou, PR China) were evaluated
in a retrospective analysis. This study was approved by the
ethics committee of the Sun Yat-sen University Cancer
Center. No consent from patients was needed.
We defined the preoperative blood hemoglobin (Hb)
concentration as the last Hb measurement before the
index operation. We also collected other clinical data for
subsequent analysis, including age, tumor type, tumor (T)
and nodal (N) status, histological grade, estrogen recep-
tor (ER) and progesterone receptor (PR) status, Human
Epidermal Growth Factor Receptor-2 (Her-2) status, body
mass index (BMI), menopausal status, type of surgery, and
the use of chemotherapy, radiotherapy, endocrinotherapy,
or targeted therapy. Patients with inadequate information,
T0 stage cancer, metastases or inoperable tumors, as
well as those treated with neoadjuvant chemotherapy or
lost to follow-up were excluded from this analysis. Finally,
2123 patients were enrolled (Figure 1). We defined pre-
operative anemia as Hb < 12.0 g/dL and mild anemia
as 9.0 ≤Hb < 12.0 g/dL according to the World Health
Organization (WHO) limits for Hb. The patients were di-
vided into two groups based on this definition: the anemic
patients group (Hb < 12.0 g/dL) and the nonanemic pa-
tient group (Hb ≥ 12.0 g/dL).156 lost to follow-up 
632 with inadequate 
information 
41 received neoadjuvant 
chemotherapy 
8 patients with other cancers  
A
 (
Figure 1 Flow chart of the patient grouping.We defined local relapse-free survival (LRFS) as the
duration from the surgery date to the date when local
relapse was diagnosed. Lymph node metastasis-free sur-
vival (LNMFS) was defined as the duration from the sur-
gery date to the date when lymph node metastasis was
diagnosed. Distant metastasis-free survival (DMFS) was
defined as the duration from the surgery date to the date
when distant metastasis was diagnosed. Relapse-free sur-
vival (RFS) was defined as the duration from the surgery
date to the date when any relapse was diagnosed and
overall survival (OS) as the duration from the surgery
date to the date of death or the last follow-up.
The clinical stages of breast cancer were performed
according to the American Joint Committee on Cancer
(AJCC) staging system [13]. Stage I included T1, N0, M0,
stage II included IIA (T0–1, N1, M0 or T2, N0, M0) and
IIB (T2, N1, M0 or T3, N0, M0) and stage III included
IIIA (T0–2, N2, M0 or T3, N1–2, M0), IIIB (T4, N0–2, M0)
and IIIC (any T, N3, M0). Stage IV was not considered
because the patients with metastases were excluded.
Statistical analysis
Patients’ characteristics (frequency distributions) were
analyzed using the χ2 test (chi-squared test). Spearman
rank correlation coefficients of risk factors for both
anemia and nonanemia groups were determined. We
also used the χ2 test to compare the local relapse, lymph
node metastasis, distant metastasis, overall relapse, and
mortality rates between the two groups. The comparison
of LRFS, LNMFS, DMFS, RFS, and OS between anemic2960 patients underwent breast 
cancer surgery (2002-2008) 




nemic group  




 (Hb≥12.0 g/dL) 
Table 1 Clinical characteristics of patient by anemia status
N = 2123 (%)
Hb < 12 g/dL Hb ≥ 12 g/dL
χ2 P
n = 535 (25.2%) n = 1588 (74.8%)
Age
≤50 1384 (65.2) 359 (67.1) 1025 (64.5) 1.152 0.283
>50 739 (34.8) 176 (32.9) 563 (35.5)
Tumor type
Invasive ductal carcinoma 1944 (91.6) 503 (94.0) 1441 (90.7) 5.561 0.018
Other 179 (8.4) 32 (6.0) 147 (9.3)
Tumor stage
T1 703 (33.1) 146 (27.3) 557 (35.1) 32.458 <0.001
T2 1146 (54.0) 284 (53.1) 862 (54.3)
T3 and T4 274 (12.9) 105 (19.6) 169 (10.6)
N stage
N0 1185 (55.8) 250 (46.7) 935 (58.8) 38.534 <0.001
N1 603 (28.4) 159 (29.7) 444 (28.0)
N2 211 (9.9) 78 (14.6) 133 (8.4)
N3 124 (5.8) 48 (9.0) 76 (4.8)
Histologic grading
G1G2 or Gx 1680 (79.1) 425 (79.4) 1255 (79.0) 0.041 0.840
G3 443 (20.9) 110 (20.6) 333 (21.0)
ER
Negative 846 (39.8) 226 (42.3) 620 (39.1) 6.385 0.041
Positive 683 (32.2) 182 (34.0) 501 (31.5)
Strongly positive 594 (28.0) 127 (23.7) 467 (29.4)
PR
Negative 654 (30.8) 168 (31.4) 486 (30.6) 8.078 0.018
Positive 906 (42.7) 249 (46.5) 657 (41.4)
Strongly positive 563 (26.5) 118 (22.1) 445 (28.0)
HER-2
Negative 1067 (50.3) 249 (46.5) 818 (51.5) 10.315 0.006
Positive 633 (29.8) 154 (28.8) 479 (30.2)
Strongly positive 423 (19.9) 132 (24.7) 291 (18.3)
BMI
Low (<18.5) 151 (7.1) 47 (8.8) 104 (6.6) 25.980 <0.001
Normal (18.5–22.9) 929 (43.8) 276 (51.6) 653 (41.1)
High (>22.9) 1043 (49.1) 212 (39.6) 831 (52.3)
Menopause
No 1318 (62.1) 352 (65.8) 966 (60.8) 4.188 0.041
Yes 805 (37.9) 183 (34.2) 622 (39.2)
Type of surgery
Modified radical mastectomy 2092 (98.5) 531 (99.3) 1561 (98.3) 2.524 0.112
Breast-conserving surgery 31 (1.5) 4 (0.7) 27 (1.7)
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Table 1 Clinical characteristics of patient by anemia status (Continued)
Chemotherapy
No 381 (17.9) 89 (16.6) 292 (18.4) 0.835 0.361
Yes 1742 (82.1) 446 (83.4) 1296 (81.6)
Radiotherapy
No 1842 (86.8) 452 (84.5) 1390 (87.5) 3.232 0.072
Yes 281 (13.2) 83 (15.5) 198 (12.5)
Hormonal therapy
No 1366 (64.3) 347 (64.9) 1019 (64.2) 0.083 0.773
Yes 757 (35.7) 188 (35.1) 569 (35.8)
Targeted therapy
No 2109 (99.3) 530 (99.1) 1579 (99.4) - 0.361a
Yes 14 (0.7) 5 (0.9) 9 (0.6)
aFisher's exact test.
Abbreviations: Hb hemoglobin, PR partial response, BMI body mass index.
Table 2 Spearman’s rank correlation of the hemoglobin
levels and various clinical characteristics
Hb P
Age 0.035 0.101
Tumor type 0.014 0.509
T stage −0.078 <0.001
N stage −0.051 0.019
Clinical stage −0.085 <0.001







Hormonal therapy 0.002 0.912
Targeted therapy −0.034 0.115
Abbreviations: Hb hemoglobin, ER estrogen receptor, PR progesterone receptor,
HER-2 Human Epidermal Growth Factor Receptor-2, BMI body mass index.
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Meier analysis with the log-rank test. Multivariate Cox
proportional hazards regression model with forward step-
wise approach was constructed to identify independent
prognostic factors. Age, tumor type, T-status, N-status,
histologic grade, ER, PR, HER-2, BMI grade, menopause,
type of surgery, anemia, sequential treatment after surgery
(chemotherapy, radiotherapy, hormonal therapy, and tar-
geted therapy) were predictive variables in the model. All
statistical analyses were performed with SPSS (Statistical
Package for the Social Sciences, IBM, NY, USA) version
16.0 software. A P value <0.05 was considered statistically
significant.
Results
Among a total of 2123 female patients qualified for the
analysis, 535 (25.2%) had a Hb level < 12.0 g/dL. The me-
dian age of the patients was 47.0 (range, 22–91) years.
There were 484 patients in stage I, 1198 in stage II, and
441 in stage III, and the corresponding number of anemic
patients at each stage was 89 (18.4%), 283 (23.6%), and
163 (37.0%), respectively. Overall, 15.8% of the patients re-
ceived locoregional radiotherapy, and 82.1% received adju-
vant chemotherapy. Patient characteristics are shown in
Table 1.
The relation between Hb levels and various risk factors
was examined by Spearman rank correlation coefficients.
As shown in Table 2, we found that there was a sig-
nificant positive correlation between Hb levels and BMI,
and a negative correlation with T- and N-status and cli-
nical stages.
After a median follow-up time of 67 months, 61 pa-
tients (2.9%) underwent local relapse, 105 (4.9%) had
lymph node metastases, and 269 (12.7%) had distant me-
tastases among 2123 breast cancer patients. Local re-
lapse was diagnosed in 7.3% of anemic patients versus1.4% of nonanemic patients (P < 0.001). For lymph node
metastasis, distant metastasis, and any relapse, the per-
centages were 12.1% versus 2.5% (P < 0.001), 26.7% ver-
sus 7.9% (P < 0.001) and 38.7% versus 9.9% (P < 0.001),
respectively. Mortality was 24.5% in anemic group versus
7.7% in nonanemic group (P < 0.001) (Table 3). The re-
lapse rate and mortality were significantly different bet-
ween the anemic and nonanemic groups.
In the univariate analysis, LRFS, LNMFS, DMFS, RFS,
and OS were significantly shorter in anemic patients than
those in nonanemic patients (P < 0.001 for all) (Figure 2).
Additionally, stratified analysis by different clinical stages
(stages I to III) of breast cancer showed that LRFS, LNMFS,
DMFS, RFS and OS were all significantly shorter in anemic
Table 3 Prevalence of relapses and deaths in patients with and without anemia
N = 2123
Hb < 12 g/dL Hb ≥ 12 g/dL
χ2 P
n = 535 (%) n = 1588 (%)
Local relapse
No 2062 496 (92.7) 1566 (98.6) 49.989 <0.001
Yes 61 39 (7.3) 22 (1.4)
Lymph node metastasis
No 2018 470 (87.9) 1548 (97.5) 78.950 <0.001
Yes 105 65 (12.1) 40 (2.5)
Distant metastasis
No 1854 392 (73.3) 1462 (92.1) 127.7 <0.001
Yes 269 143 (26.7) 126 (7.9)
Any relapse
No 1758 328 (61.3) 1430 (90.1) 232.2 <0.001
Yes 365 207 (38.7) 158 (9.9)
Death
No 1869 404 (75.5) 1465 (92.3) 106.5 <0.001
Yes 254 131 (24.5) 123 (7.7)
Abbreviation: Hb hemoglobin.
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tients, 2104 had mild anemia (9.0 ≤Hb < 12.0 g/dL). Sur-
vivals were also significantly shorter even in patients with
mild anemia (Figure 6).
Multivariate analysis with all relevant prognostic factors
in a Cox proportional hazards regression model showed
that preoperative anemia was a significant prognostic
factor in breast cancer patients (Table 4). T-status (≥T3),
N-status (N1, N2), strongly positive PR status and HER-2
positivity were significantly associated with LRFS, and
anemic patients had a 4.939-fold increased relative risk of
developing local relapse compared with nonanemic pa-
tients. Only the N-status (N1, N2) was significantly asso-
ciated with LNMFS, with a 5.160-fold increased relative
risk of developing lymph node metastasis for anemic pa-
tients compared with nonanemic patients. With respect to
DMFS and OS, T-status (≥T3) and N-status (N1-N3) still
had significant associations, and the relative risks of devel-
oping distant metastasis and death in the anemic group
were 3.192-fold and 2.849-fold higher than those in the
nonanemic group, respectively. For RFS, T-status (≥T3),
N-status (N1–N3), and strongly positive PR status were
shown to be significant prognostic factors. Anemic pa-
tients had a 4.104-fold increased relative risk of developing
any relapse compared with nonanemic patients.
Discussion
Preoperative anemia has been reported to be associated
with poor prognosis in many types of tumors [6,14]. In
our present study, a low preoperative Hb level was shown
to be associated with local and distant relapses in breastcancer patients. Shorter survival was also observed in
anemic patients. To the best of our knowledge, our study
was the first to discover that preoperative Hb levels were
associated with tumor (T) and nodal (N) status of breast
cancer and BMI. Further, the most important study fin-
ding was that preoperative anemia was shown to be an in-
dependently prognostic factor for LRFS, LNMFS, DMFS,
RFS, and OS in breast cancer patients, even in the same
clinical stage or at lower stages.
Causes of anemia in cancer patients are multifactorial
and can be considered as results of cancer invasion, in-
duced by treatment (after radiotherapy or chemotherapy),
or chronic kidney disease [15]. Among the three factors
mentioned above, the first one is the largest contributor.
Cancer itself can cause or exacerbate anemia in several
ways [16]. Cancer cells may suppress hematopoiesis via
bone marrow infiltration directly. They also generate cy-
tokines that lead to functional iron deficiency, which de-
creases the production and shorten the survival of red
blood cells [17]. Also, chronic blood loss at tumor sites
through cancer cells infiltration can exacerbate anemia.
Other indirect effects include nutritional deficiencies of
iron, folate, and vitamin B12 secondary to anorexia or
hemolysis by immune-mediated antibodies. For the factors
mentioned above, it is plausible that preoperative anemia
is more frequent in higher clinical stages and low BMI in
association with malnutrition.
Many studies supported that pre-treatment Hb levels
during adjuvant or neoadjuvant chemotherapy were re-
lated to the prognosis of breast cancer. However, few
studies focused on the preoperative Hb levels [12,18,19].
Figure 2 LRFS, LNMFS, DMFS, RFS, and OS of patients with and without anemia. A. LRFS for patients with Hb≥ 12 g/dL versus Hb < 12 g/dL.
B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL. C. DMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL. D. RFS for patients with
Hb ≥12 g/dL versus Hb <12 g/dL. E. OS for patients with Hb ≥12 g/dL versus Hb <12 g/dL.
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an independent risk factor of disease-free survival and
overall survival in 336 early-stage breast cancer patients
[11]. Our results not only supported their conclusion
but also showed that preoperative anemia was associated
with local relapse-free survival, lymph node metastasis-
free survival, and distant metastasis-free survival in a lar-
ger cohort.
There are several possible mechanisms by which anemia
may reduce survival, and hypoxia is the most important
one. Anemia can reduce the capacity of the blood totransport oxygen (O2), further contributing to the deve-
lopment of hypoxia. Hypoxia is a common characteristic
of locally advanced solid tumors that has been associated
with greater recurrence, less locoregional control, di-
minished therapeutic responses, and lower overall and
disease-free survival [20,21]. The association between the
blood Hb concentration (cHb) and the tumor oxygenation
status has been examined [22-27]. The median pO2 values
in breast cancer tumors are lower than those in the nor-
mal breast, which exponentially increase with increasing
cHb values [28]. In normal breast tissue, the O2 tensions
Figure 3 LRFS, LNMFS, DMFS, RFS, and OS of patients in stage I with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage I. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. C. DMFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage I. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. E. OS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage I.
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in breast cancer tissue, the median pO2 is 28 mmHg. Fur-
ther, nearly 60% of breast cancers contain hypoxic tissue
areas with pO2 values <2.5 mmHg [29].
Hypoxia can lead to structural and functional abnorma-
lities in the tumor microvasculature, an adverse diffusion
geometry and tumor-related anemia result in a reduced
O2 transport capacity of the blood [30]. A key regulator of
this process is hypoxia-inducible factor-1 (HIF-1). HIF-1
is a molecular determinant that responds to hypoxia. Itsexpression increases as the pathologic stages progress, and
it is higher in poorly differentiated lesions than in well-
differentiated lesions [31]. HIF-1 activity mediates angio-
genesis [32-34], epithelial-mesenchymal transition [25],
genetic mutations, resistance to apoptosis, and resistance
to radiotherapy and chemotherapy [34] in regions of intra-
tumoral hypoxia. More recent studies have suggested that
HIF-1α is a significant positive regulator of tumor progres-
sion, metastasis, and poor patient prognosis [26,32,33],
and higher expression of HIF-1α has been shown to
Figure 4 LRFS, LNMFS, DMFS, RFS, and OS for patients in stage II with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage II. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. C. DMFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage II. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. E. OS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage II.
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[35,36]. This effect was independent of standard prog-
nostic factors, such as tumor stage and nodal status [37].
Some results of our study may be attributed to hypoxia
and HIF-1α activity. It was interesting that preoperative
Hb levels were negatively related to tumor (T) and nodal
(N) status of breast cancer, which were both traditional
prognostic factors of breast cancer. However, anemia alsoimpaired various survival outcomes independently even in
the same clinical stage.
Although preoperative anemia was not related to the se-
quential postoperative treatment in our study, most of the
data supported the notion that pretreatment anemia may
influence the effects of sequential postoperative treatment.
The reason may be that preoperative anemia contributes
to hypoxia in cancer cells. There is increasing evidence
Figure 5 LRFS, LNMFS, DMFS, RFS, and OS for patients in stage III with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage III. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. C. DMFS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage III. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. E. OS for patients with Hb ≥12 g/dL versus
Hb <12 g/dL in stage III.
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therapy, chemotherapy, and targeted therapy. Thus, the
potential for invasion, metastasis and patient mortality is
increased further [25-27,30]. Hypoxia leads to therapeutic
resistance directly through a lack of O2, which radiation
and some chemotherapeutic drugs require to exert their
cytotoxicity. Hypoxia also leads to resistance indirectly
through changes in cellular metabolism, proliferationkinetics, the cell-cycle position, the hypoxia-driven prote-
ome, and genome and clonal selection [21,27].
Although hypoxia may be a reasonable explanation for
the association between anemia and survival of breast
cancer, there was no direct evidence of hypoxia in cancer
cells in our large population study. Emerging new tools that
can measure the local Hb level and O2 tension directly in
tumor tissues may solve this problem in the future. Our
Figure 6 LRFS, LNMFS, DMFS, RFS, and OS for patients without anemia versus mild anemia. A. LRFS for patients with Hb ≥12 g/dL versus
9 < Hb <12 g/dL. B. LNMFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. C. DMFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL.
D. RFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. E. OS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL.
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the complex mechanisms of hypoxia in breast cancer.
Since preoperative anemia was associated with poor prog-
nosis in breast cancer patients in our study, would patients
benefit from anemia treatment preoperatively? Or could we
improve the prognosis after administering treatment for
anemia? The answer to this question is somewhat ambiguous
because of the complexity of anemia. For most of patients
with breast cancer without chemotherapy, preoperative
anemia was caused by multiple etiologies, including blood
loss, functional iron deficiency, erythropoietin deficiency
secondary to renal disease, tumoral marrow involvement,well as other factors. Evaluation of anemia should be per-
formed carefully before treatment because an unsuitable
treatment might lead to adverse effects. The most common
treatment options for anemic patients include iron therapy,
red cell transfusion, and erythropoietic-stimulating agents.
For iron therapy, nutritional status (iron, total iron binding
capacity, ferritin, transferrin saturation, folate, and vitamin
B12) and renal function should be evaluated. Only absolute
iron deficiency will benefit from intravenous or oral iron
monotherapy [38,39]. Unfortunately the absence of data
regarding the nutritional status and renal function of our
patients impeded further analysis.
Table 4 Multivariate analysis of prognostic factors for LRFS, LNMFS, DMFS, RFS, and OS
LRFS LNMFS DMFS RFS OS
HR (95% CI) P HR (95% CI) P 95% CI P 95% CI P 95% CI P
T stage
T1 Ref NS NS Ref Ref Ref
T2 1.045 (0.532–2.050) 0.899 NS NS 1.333 (0.962–1.847) 0.084 1.287 (0.976–1.697) 0.074 1.291 (0.925–1.803) 0.134
≥T3 2.676 (1.267–5.653) 0.010 NS NS 1.983 (1.347–2.920) 0.001 2.021 (1.455–2.807) <0.001 2.020 (1.371–2.975) <0.001
N stage
N0 Ref Ref Ref Ref Ref
N1 2.601 (1.366–4.963) 0.004 2.235 (1.366–3.657) 0.001 2.040 (1.493–2.788) <0.001 2.009 (1.544–2.615) <0.001 1.942 (1.404–2.687) <0.001
N2 2.708 (1.122–6.534) 0.027 3.742 (2.058–6.805) <0.001 3.484 (2.358–5.147) <0.001 3.016 (2.152–4.225) <0.001 4.200 (2.854–6.181) <0.001
N3 2.450 (0.859–6.989) 0.094 2.045 (0.912–4.487) 0.083 4.822 (3.175–7.323) <0.001 3.856 (2.672–5.565) <0.001 5.083 (3.307–7.812) <0.001
ER
Negative Ref NS NS Ref Ref Ref
Positive 0.525 (0.261–1.057) 0.071 NS NS 0.670 (0.479–0.937) 0.019 0.726 (0.547–0.965) 0.027 0.845 (0.598–1.194) 0.340
Strongly positive 0.340 (0.144–0.803) 0.014 NS NS 0.804 (0.537–1.206) 0.292 0.757 (0.534–1.074) 0.119 0.566 (0.360–0.890) 0.014
PR
Negative Ref NS NS NS NS Ref NS NS NS
Positive 1.709 (0.826–3.535) 0.149 NS NS NS NS 1.409 (1.066–1.861) 0.016 NS NS
Strongly positive 2.989 (1.236–7.228) 0.015 NS NS NS NS 0.899 (0.611–1.322) 0.588 NS NS
HER-2
Negative Ref NS NS NS NS NS NS NS NS
Positive 2.179 (1.232–3.855) 0.007 NS NS NS NS NS NS NS NS
Strongly positive 0.651 (0.292–1.451) 0.294 NS NS NS NS NS NS NS NS
Hormonal therapy NS NS 0.537 (0.335–0.859) 0.009 NS NS 0.733 (0.575–0.933) 0.012 0.682 (0.503–0.926) 0.014
Anemia 4.939 (2.875–8.484) <0.001 5.160 (3.428–7.767) <0.001 3.192 (2.489–4.094) <0.001 4.104 (3.310–5.089) <0.001 2.849 (2.205–3.680) <0.001
Abbreviations: LRFS local relapse-free survival, LNMFS lymph node metastasis-free survival, DMFS distant metastasis-free survival, RFS relapse-free survival, OS overall survival, ER estrogen receptor, PR progesterone
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http://www.biomedcentral.com/1471-2407/14/844Red cell transfusion is an acceptable treatment option for
anemic breast cancer patients, especially for those requiring
rapid improvement of Hb levels. However, large-scale stud-
ies involving cancer patients found that red cell transfusion
was associated with increased thrombosis risk as well as
increased mortality risk [40]. Additionally, mild anemia
accounted for 99% anemic patients in this study; thus,
transfusions might not be necessary. As for erythropoietic-
stimulating agent therapy, it was suitable only for patients
receiving palliative, myelosuppressive chemotherapy with a
Hb <10 g/dL and without absolute iron deficiency [39].
Notably, there were few reports focusing on the relationship
between preoperative Hb and prognosis. However, most
treatments for anemia were derived from the prognostic
outcomes of patients with chemotherapy-induced anemia.
Thus, whether preoperative anemia and chemotherapy-
induced anemia are both associated with poor prognosis of
patients with breast cancer remains to be clarified. The
question of what is the best approach for patients with
preoperative anemia remains unanswered. Therefore,
further studies will be needed to answer these questions.
Conclusions
Preoperative anemia is a negative prognostic factor for
survival of patients with breast cancer. However, it still
merits further experimental and clinical investigations.
Abbreviations
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